GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Merck & Co., Inc.’s HPV Vaccine, Available to Developing Countries through UNICEF Tender

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has been awarded a significant portion of the UNICEF human papillomavirus (HPV) vaccine tender, and will provide sustained supply of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] to GAVI-eligible countries. This agreement follows the GAVI Alliance’s earlier announcement that HPV vaccines would be included in its portfolio for the first time. GAVI is expected to support the introduction of HPV vaccination in 28 countries by the end of 2017.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC